363139-46-2

Upstream product

• 127854-45-9 (4S,5S)-2,2-Dioxo-2λ⁶-[1,3,2]dioxathiolane-4,5-dicarboxylic acid diisopropyl ester 
• 6921-34-2 benzylmagnesium chloride 
• 100-39-0 benzyl bromide 
• 62961-64-2 D-(-)-diisopropyl tartrate 
• 83541-68-8 2S-Hydroxybutan-1,4-dioic acid diisopropyl ester 

Downstream Products

• 363139-55-3 (2R,2'S,4'S)-2-[4-benzyl-2-(tert-butyl)-5-oxo-1,3-dioxolan-4-yl]-3-phenylpropanoic acid 
• 136010-67-8 (2R,3S)-2-benzyl-3-hydroxysuccinic acid 
• 363139-63-3 (3S,4S)-3,4-Dibenzyl-tetrahydro-furan-2,3-diol 

Relevant academic research and scientific papers

N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF

The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.

Enantioselective synthesis of α-hydroxylated enterolactone and analogs

A short and general synthesis of enantiomerically pure α-hydroxylated lactone lignans starting from commercially available iPr malate is presented. Key reactions are two stereoselective alkylations of malic acid derivatives. Some enhancements of the alkylation of malic acid esters and a general extension of the alkylation of dioxolanones is reported. Proof of the stereochemical outcome of the alkylation reactions is provided by X-ray diffraction analysis of α-hydroxy-α,β-dibenzyl-γ-butyrolactone, the first crystal structure of an enantiomerically pure α-hydroxylated lactone lignan.